Luxa Biotechnology published Phase 1/2a clinical trial data showing promising safety and efficacy of its adult retinal pigment epithelial stem cell (RPESC-RPE) transplantation in dry age-related macular degeneration (AMD). Six participants receiving low-dose cell injections experienced significant vision improvements of up to +21 ETDRS letters with sustained benefit at 12 months and no severe adverse events. The therapy also received FDA regenerative medicine advanced therapy (RMAT) designation, highlighting its potential in treating a condition lacking approved vision-improving treatments.